Skip to content
Screener

McKesson MCK Oncology & Multispecialty — Subtotal

Similar metrics at other companies

ESAB logo
ESABAmericas: — Subtotal
$10.37M—
ESAB logo
ESABEMEA and APAC Segment — Subtotal
$35K—
Eli Lilly logo
LLYOncology — Revenue
$2.57B+6.5%
BillionToOne, Inc. logo
BLLNOncology — Revenue
$13.66M+176%
Lantheus Holdings logo
LNTHOncology — Revenue
$240.37M-4.1%
Tredegar logo
TGSubtotal — Other
-$384K-131%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+16.8%
Enterprise value$110.42B+14.5%
P/E22.4×-5.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%—
Debt / equity2×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept mck:GrossProfitNetOfExpensesIncludingOtherIncome.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234
(In millions)Three Months Ended June 30, 2026Three Months Ended June 30, 2025
Total other segment expense, net$103,804$96,534
Segment operating profit
North American Pharmaceutical$903$594
Oncology & Multispecialty325212
Prescription Technology Solutions226253
Medical-Surgical Solutions122221
Other—13
Subtotal1,5761,293

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's oncology & multispecialty — subtotal?
McKesson (MCK) reported oncology & multispecialty — subtotal of $325M in Q2 2026.
How has McKesson's oncology & multispecialty — subtotal changed year-over-year?
McKesson's oncology & multispecialty — subtotal increased by 53.3% year-over-year, from $212M to $325M.
What is the long-term trend for McKesson's oncology & multispecialty — subtotal?
Over 2 years (2024 to 2026), McKesson's oncology & multispecialty — subtotal has grown at a 27.5% compound annual growth rate (CAGR), from $707M to $1.15B.
What does oncology & multispecialty — subtotal mean?
Represents the aggregate financial performance or operational sub-total for the Oncology and Multispecialty segment before final corporate-level adjustments. This metric serves as a key indicator of the segment's direct contribution to the company's overall financial results. It reflects the core profitability or operational scale of the business unit.

Ask your AI about McKesson's oncology & multispecialty — subtotal.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude